Table 11 Neromuscular effects of mivacurium in paediatric patients in group C (mean ± SD, S)
From: The efficacy and safety of mivacurium in pediatric patients
Subgroups | n | Onset time | T1 5% recovery | T1 25% recovery | Recovery index | TOF ratio 90% |
|---|---|---|---|---|---|---|
Group 9 | 34 | 183 ± 57 | 263 ± 80 | 693 ± 188 | 313 ± 102 | 1014 ± 242 |
Group 10 | 36 | 172 ± 55 | 277 ± 89 | 741 ± 185 | 311 ± 91 | 1033 ± 215 |
Group 11 | 35 | 161 ± 51 | 296 ± 95 | 800 ± 206# | 315 ± 94 | 901 ± 259 |
Group 12 | 36 | 160 ± 50 | 313 ± 96 | 743 ± 172 | 293 ± 91 | 958 ± 255 |